Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

Journal of Surgical Oncology

Volumn 66, Issue 3, 1997, Pages 215-220

  Roseman, Barry J ^a   Buzdar, Aman U ^a   Singletary, S Eva ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Androstenedione analogs and derivatives ; Antineoplastic agents, hormonal pharmacology ; Antineoplastic agents, hormonal therapeutic use ; Aromatase antagonists and inhibitors ; Breast neoplasms drug therapy ; Estrogen antagonists therapeutic use ; Neoplasms, hormone dependent drug therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; FADROZOLE; GESTAGEN; GONADORELIN AGONIST; LETROZOLE; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; VOROZOLE;

ADVANCED CANCER; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; MENSTRUATION DISORDER; METASTASIS; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VAGINA DISCHARGE; VOMITING;

AMINOGLUTETHIMIDE; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 0030666998     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199711)66:3<215::AID-JSO11>3.0.CO;2-0     Document Type: Review

References (36)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestion for a new method of treatment, with illustrative cases. Lancet 1896;2:104-107.
2. Report from the Council on Drugs: Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of nine hundred forty-four patients. JAMA 1960;172:135-147.
3. Winston MJ, Knight RK, Rubens RD: Corticosteroids for elderly patients with breast cancer. Cancer 1981;48:883-887.
4. Moore FD, VanDevanter SB, Boyden CM, et al.: Adrenalectomy with chemotherapy in the treatment of advanced breast cancer: Objective and subjective response rates, duration and quality of life. Surgery 1974;76:376-388.
5. McGuire WO, Chamness GC: Studies on the estrogen receptor in breast cancer. Adv Exp Med Biol 1973;36:113-136.
6. Englesman E, Persijn JP, Korsten CB, Cleton FJ: Estrogen receptor in human breast cancer tissue and response to endocrine therapy. Br Med J 1973;266:750-752.
7. Sedlacek SM, Horwitz KB: The rule of progestins and progesterone receptors in the treatment of breast cancer. Steroids 1984;44: 467-484.
8. Litherland S, Jackson IM: Antiestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1988;15:183-194.
9. Henderson IC: Endocrine therapy of metastatic breast cancer. Breast Dis 1991;2:559-603.
10. Buckly MM, Goa KL; Tamoxifen, a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37:451-490.
11. Jaiwesimi IA, Buzdar AU, Decker DA, Hortobagyi GN: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 1995;13:513-529.
12. Vogel C: Hormonal approaches to breast cancer treatment and prevention: An overview. In "Aromatase Inhibitors in the Treatment of Advanced Breast Cancer." Proceedings of the Eighteenth Annual San Antonio Breast Cancer Symposium; 1995 Dec 10:1-13.
13. Jordan VC: "Breast Cancer Update. Antiestrogens: Past, Present, and Future." Highlights from a roundtable discussion; Boston, Massachusetts, July 20, 1996. Wilmington, DE: Zeneca Pharmaceuticals, p 2.
14. Love RR, Barden HS, Mazess RB, et al.: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-2588.
15. Love RR, Wiebe DA, Feyzi JM, et al.: Effects of tamoxifen on cardiovascular risk factors in women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-1539.
16. Rutqvist LE, Mattson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-1406.
17. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Monogr Natl Cancer Inst 1992;11:117-120.
18. Fornander T, Rutqvist LE, Cedermark B, et al.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-120.
19. Rutqvist LE, Johansson H, Signomklao T, et al.: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-651.
20. King CM: Tamoxifen and the induction of cancer. Carcinogenesis 1995;16:1449-1454.
21. Williams G: Tamoxifen experimental carcinogenicity studies: Implications for human effects. Proc Soc Exp Biol Med 1995;208: 141-143.
22. Cohen I, Beyth Y, Tepper R, et al.: Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: A new entity? Gynecol Oncol 1995;58:86-91.
23. Parazzini F, Colli E, Scantigna M, et al.: Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: A quantitative review of published randomized clinical trials. Oncology 1993;50:483-489.
24. Ibrahim NK, Buzdar A: Aromatase inhibitors: Current status. Am J Clin Oncol 1995;18:407-417.
25. Bolufer P, Ricart E, Lluch E, et al.: Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol 1992;10:438-446.
26. Buzdar A: Aromatase inhibitors in metastatic breast cancer. In "Aromatase Inhibitors in the Treatment of Advanced Breast Cancer." Proceedings of the Eighteenth Annual San Antonio Breast Cancer Symposium: 1995 Dec 10:29-33.
27. Buzdar A, Plourde P, Jones S, et al.: A randomized phase III study of the selective aromatase inhibitor Arimidex (A) (ZD 1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer. Breast 1995;4:256-259.
28. Buzdar A, Jonat A, Howell A, et al.: Anastrozole (Arimidex), a potent and selective aromatase inhibitor, versus megestrol acetate (Megace) in postmenopausal women with advanced breast cancer: Results of an overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-2011.
29. Jonat W, Howell A, Blomqvist CP, et al.: A randomized trial of the new specific aromatase inhibitor Arimidex versus megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 1995;14:108.
30. Jonat W, Howell A, Blomqvist C, et al.: A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal women with advanced breast cancer. Eur J Cancer 1996;32A:404-412.
31. Buzdar AU, Smith R, Vogel C, et al.: Fadrozole HC1(CGS-16949A) versus megestrol acetate in postmenopausal patients with metastatic breast carcinoma: Results of two randomized, double-blind, controlled multi-institutional trials. Cancer 1996;77: 2503-2513.
32. Thurlimann B, Beretta K, Bacchi M, et al.: First line fadrozole HC1 (CGS-16949A) versus tamoxifen in advanced breast cancer: prospective randomized study SAKK 20/88 (abst 90). Proc Am Soc Clin Oncol 1995;14:98.
33. Coombes RC, Wilkinson JR, Bliss JM, et al.: 4-hydroxyan-drostenedione in the prophylaxis of N methyl-N-nitrosourea induced mammary tumourigenesis. Br J Cancer 1991;64:247-250.
34. Masamura S, Adlercreutz H, Harvey H, et al.: Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 1994;33:19-26.
35. Gross PE, Gwyn KM: Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994;12:2460-2470.
36. Harvey HER, Lipton A, Santen RJ, et al.: Phase I and phase II clinical trials of fadrozole hydrochloride in postmenopausal women with metastatic breast cancer. Adv Clin Oncol 1994;2: 155-158.